Payment overview · 2025
General Payments
$325.58
11 reported records · 8 companies
Healthcare provider profile · identity verified
Stormiee Danielle Eldred, FNP- BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CARTHAGE, TN · NPI 1750687422
Verified facts
What the public records show
CMS Open Payments records show Stormiee Danielle Eldred, FNP- BC received $325.58 in general payments during 2025 across 11 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Xarelto by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 38.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.59 | 20.4% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.88 | 9.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.68 | 8.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.97 | 7.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.18 | 6.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.64 | 5.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.64 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $325.58 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.59 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.88 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.68 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 777 | 106 |
| Furosemide | Furosemide | 474 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 298 | 52 |
| Trazodone Hcl | Trazodone Hcl | 295 | 57 |
| Omeprazole | Omeprazole | 257 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 246 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 44 |
| Tramadol Hcl | Tramadol Hcl | 220 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 218 | 49 |
| Lorazepam | Lorazepam | 217 | 32 |
| Sertraline Hcl | Sertraline Hcl | 213 | 34 |
| Mirtazapine | Mirtazapine | 196 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 38 |
| Eliquis | Apixaban | 188 | 48 |
| Glipizide | Glipizide | 181 | 45 |
| Losartan Potassium | Losartan Potassium | 179 | 28 |
| Potassium Chloride | Potassium Chloride | 176 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 39 |
| Prednisone | Prednisone | 168 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 31 |
| Donepezil Hcl | Donepezil Hcl | 157 | 32 |
| Alprazolam | Alprazolam | 154 | 22 |
| Spironolactone | Spironolactone | 143 | 38 |
| Memantine Hcl | Memantine Hcl | 141 | 29 |
| Allopurinol | Allopurinol | 140 | 23 |
| Lisinopril | Lisinopril | 138 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 135 | 22 |
| Buspirone Hcl | Buspirone Hcl | 122 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 41 |
| Carvedilol | Carvedilol | 105 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 16 |
| Lactulose | Lactulose | 92 | 19 |
| Bumetanide | Bumetanide | 91 | 15 |
| Nifedipine Er | Nifedipine | 88 | 16 |
| Simvastatin | Simvastatin | 86 | 15 |
| Famotidine | Famotidine | 81 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 12 |
| Meloxicam | Meloxicam | 74 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 16 |
| Bethanechol Chloride | Bethanechol Chloride | 70 | 13 |
| Montelukast Sodium | Montelukast Sodium | 70 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 15 |
| Atenolol | Atenolol | 67 | 11 |
| Clonazepam | Clonazepam | 67 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 48 |
| Olanzapine | Olanzapine | 62 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 60 | 39 |
| Xarelto | Rivaroxaban | 60 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | suppressed |
| Cephalexin | Cephalexin | 56 | 45 |
| Divalproex Sodium | Divalproex Sodium | 54 | 14 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 23 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | 11 |
| Dexamethasone | Dexamethasone | 41 | 35 |
| Metformin Hcl | Metformin Hcl | 41 | 14 |
| Morphine Sulfate | Morphine Sulfate | 41 | 14 |
| Temazepam | Temazepam | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 21 |
| Finasteride | Finasteride | 38 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | 22 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 37 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 37 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 31 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 36 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 33 | suppressed |
| Nystatin | Nystatin | 33 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 19 |
| Risperidone | Risperidone | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 24 |
| Linzess | Linaclotide | 29 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 14 |
| Xifaxan | Rifaximin | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 23 |
| Azithromycin | Azithromycin | 26 | 20 |
| Calcitriol | Calcitriol | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | 12 |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Xcopri | Cenobamate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $325.58 · 11 records | Otsuka America Pharmaceutical, Inc. | GEMTESA, INSPIRE, Kerendia, REXULTI, SPRAVATO, TZIELD, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error